Treating hepatocellular carcinoma with sorafenib in liver transplant patients

An initial experience

R. F. Saidi, S. A. Shah, A. P. Rawson, St Grossman, Bilal Piperdi, A. Bozorgzadeh

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC). However, there are no data reported on its use in HCC patients with localized disease who have undergone orthotopic liver transplantation (OLT). Herein, we have reviewed our initial experience with 7 HCC patients who were candidates for OLT and were treated with sorafenib. Treating liver transplant patients with sorafenib appeared to be safe based upon our limited experience. There is a strong need for clinical trials to comprehensively study the safety of sorafenib before OLT.

Original languageEnglish (US)
Pages (from-to)4582-4584
Number of pages3
JournalTransplantation Proceedings
Volume42
Issue number10
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Liver Transplantation
Transplants
Liver
Clinical Trials
Safety
sorafenib
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Treating hepatocellular carcinoma with sorafenib in liver transplant patients : An initial experience. / Saidi, R. F.; Shah, S. A.; Rawson, A. P.; Grossman, St; Piperdi, Bilal; Bozorgzadeh, A.

In: Transplantation Proceedings, Vol. 42, No. 10, 12.2010, p. 4582-4584.

Research output: Contribution to journalArticle

Saidi, R. F. ; Shah, S. A. ; Rawson, A. P. ; Grossman, St ; Piperdi, Bilal ; Bozorgzadeh, A. / Treating hepatocellular carcinoma with sorafenib in liver transplant patients : An initial experience. In: Transplantation Proceedings. 2010 ; Vol. 42, No. 10. pp. 4582-4584.
@article{bf8b928dc3f741ca8e20bd341f960df4,
title = "Treating hepatocellular carcinoma with sorafenib in liver transplant patients: An initial experience",
abstract = "Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC). However, there are no data reported on its use in HCC patients with localized disease who have undergone orthotopic liver transplantation (OLT). Herein, we have reviewed our initial experience with 7 HCC patients who were candidates for OLT and were treated with sorafenib. Treating liver transplant patients with sorafenib appeared to be safe based upon our limited experience. There is a strong need for clinical trials to comprehensively study the safety of sorafenib before OLT.",
author = "Saidi, {R. F.} and Shah, {S. A.} and Rawson, {A. P.} and St Grossman and Bilal Piperdi and A. Bozorgzadeh",
year = "2010",
month = "12",
doi = "10.1016/j.transproceed.2010.09.147",
language = "English (US)",
volume = "42",
pages = "4582--4584",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Treating hepatocellular carcinoma with sorafenib in liver transplant patients

T2 - An initial experience

AU - Saidi, R. F.

AU - Shah, S. A.

AU - Rawson, A. P.

AU - Grossman, St

AU - Piperdi, Bilal

AU - Bozorgzadeh, A.

PY - 2010/12

Y1 - 2010/12

N2 - Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC). However, there are no data reported on its use in HCC patients with localized disease who have undergone orthotopic liver transplantation (OLT). Herein, we have reviewed our initial experience with 7 HCC patients who were candidates for OLT and were treated with sorafenib. Treating liver transplant patients with sorafenib appeared to be safe based upon our limited experience. There is a strong need for clinical trials to comprehensively study the safety of sorafenib before OLT.

AB - Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC). However, there are no data reported on its use in HCC patients with localized disease who have undergone orthotopic liver transplantation (OLT). Herein, we have reviewed our initial experience with 7 HCC patients who were candidates for OLT and were treated with sorafenib. Treating liver transplant patients with sorafenib appeared to be safe based upon our limited experience. There is a strong need for clinical trials to comprehensively study the safety of sorafenib before OLT.

UR - http://www.scopus.com/inward/record.url?scp=78650460656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650460656&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2010.09.147

DO - 10.1016/j.transproceed.2010.09.147

M3 - Article

VL - 42

SP - 4582

EP - 4584

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -